1. Zhu, Xiao-Na, Wei, Yu-Sheng, Yang, Qian, Yu, Yun, Chen, Guo-Qiang. 2023. FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia. In Journal of hematology & oncology, 16, 9. doi:10.1186/s13045-023-01400-0. https://pubmed.ncbi.nlm.nih.gov/36774506/
2. De, Sarmishtha, Holvey-Bates, Elise G, Mahen, Kala, Willard, Belinda, Stark, George R. . The ubiquitin E3 ligase FBXO22 degrades PD-L1 and sensitizes cancer cells to DNA damage. In Proceedings of the National Academy of Sciences of the United States of America, 118, . doi:10.1073/pnas.2112674118. https://pubmed.ncbi.nlm.nih.gov/34795058/
3. Johmura, Yoshikazu, Harris, Alexander S, Ohta, Tomohiko, Nakanishi, Makoto. 2020. FBXO22, an epigenetic multiplayer coordinating senescence, hormone signaling, and metastasis. In Cancer science, 111, 2718-2725. doi:10.1111/cas.14534. https://pubmed.ncbi.nlm.nih.gov/32536008/
4. Ge, Meng-Kai, Zhang, Na, Xia, Li, Chen, Guo-Qiang, Shen, Shao-Ming. 2020. FBXO22 degrades nuclear PTEN to promote tumorigenesis. In Nature communications, 11, 1720. doi:10.1038/s41467-020-15578-1. https://pubmed.ncbi.nlm.nih.gov/32249768/
5. Li, Minle, Chen, Xuan, Qu, Pengfei, Pan, Zhen-Qiang, Bai, Jin. 2024. FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR. In Proceedings of the National Academy of Sciences of the United States of America, 121, e2402035121. doi:10.1073/pnas.2402035121. https://pubmed.ncbi.nlm.nih.gov/39485803/
智鼠故事 
